Compare Ishares Msci Spain ETF (EWP) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs GSK plc — how do they compare? Ishares Msci Spain ETF trades at $59.23, while GSK plc trades at $52.85 (market cap $101.34B). The key difference: GSK plc pays a 3.49% dividend while Ishares Msci Spain ETF pays none, and Ishares Msci Spain ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| EWP | GSK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $60.28 | $61.18 |
52-Week Low | $43.90 | $36.20 |
Market Cap | — | $101.34B |
Enterprise Value | — | $121.95B |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP trades at $59.26, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend, supported by strong moving average alignment, while oscillators remain neutral. The stock exhibits tight support at $59 and resistance at $60. A dividend of $0.92 per share is scheduled for payment on June 18, 2026.
The outlook for EWP is cautiously optimistic due to bullish technicals and upcoming dividend returns. Key risks include European economic sensitivity to energy price volatility and potential interest rate impacts. Investors should monitor ECB policy decisions and regional economic performance for directional cues.
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
